carbostyril has been researched along with Prostatic Neoplasms, Castration-Resistant in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (88.89) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Albany, C; Babu, S; Bendell, JC; Callies, S; Cultrera, JL; Donoho, GP; Goodman, OB; Guba, SC; Lin, BK; Mehlhaff, BA; Morris, DS; Percent, IJ; Schnadig, ID; Shore, ND; Sieber, PR; Sweeney, CJ; Szpurka, AM; Wacheck, V; Zhang, W | 1 |
| Alhawas, L; Amin, KS; Banerjee, PP; Salla, B | 1 |
| Baton, F; Bellmunt, J; Chowdhury, S; Climent, MA; Daugaard, G; Dumez, H; Fizazi, K; Flechon, A; Germann, N; Guida, A; Ladoire, S; Liutkauskiene, S; Matouskova, M; Moe, M; Penel, N; Sengeløv, L; Stachurski, L; Sternberg, CN; Thiery-Vuillemin, A; Ulys, A | 1 |
| Choi, YJ; Kim, BS; Kim, HG; Kim, HS; Kim, KH; Lee, HJ; Lee, HY; Lee, JL; Lee, KH; Park, KH; Park, SH; Shin, DY; Song, HS | 1 |
| He, P; Shen, W; Wang, Y; Zhang, H; Zhou, Z | 1 |
| Gong, P; He, M; Liu, H; Liu, M; Liu, X; Ma, J; Ren, Z; Wang, Q; Xiong, W; Yang, X; Zhang, X; Zhou, G | 1 |
| Agarwal, N; Bellmunt, J; DiLorenzo, G; Sonpavde, G; Vogelzang, NJ; Zhang, TY | 1 |
| Burggraaf, J; Osanto, S; van Poppel, H | 1 |
| Armstrong, AJ; Assikis, V; Belkoff, L; Carducci, MA; Damber, JE; Forsberg, G; Gingrich, JR; Häggman, M; Nordle, Ö; Pili, R; Polikoff, J; Stadler, WM | 1 |
| Aparicio, A; Cao, X; Chinnaiyan, AM; Corn, PG; Efstathiou, E; Iyer, MK; Kundra, V; Li Ning Tapia, EM; Logothetis, CJ; McKeehan, W; Navone, NM; Palanisamy, N; Ravoori, MK; Robinson, DR; Starbuck, MW; Tapia, EM; Troncoso, P; Vazquez, ES; Wan, X; Wang, F; Wu, YM; Yang, J; Zurita, AJ | 1 |
| Dalrymple, SL; Hammers, H; Isaacs, JT; Leanderson, T; Olsson, A; Rosen, DM | 1 |
| Armstrong, AJ; Carducci, MA; Damber, JE; Edenbrandt, L; Forsberg, G; Hansen, M; Kaboteh, R; Morris, MJ; Nordle, Ö; Pili, R; Stadler, WM | 1 |
| Houédé, N; Irani, J | 1 |
| Chien, WS; Hsieh, DJ; Hsieh, YL; Huang, CY; Kuo, SC; Lin, TH; Shen, CH; Shen, CY; Ting, WJ; Wen, SY; Wu, HC; Yao, CH | 1 |
| Damber, JE; Hagberg Thulin, M; Magnusson, LU; Olsson, A; Plas, P; Welén, K | 1 |
| Agarwal, N; Armstrong, A; Baton, F; Bögemann, M; Brize, A; Carducci, M; Chowdhury, S; Delva, R; Gallardo, E; Harza, M; Huddart, R; Hutson, T; James, N; Khvorostenko, D; Lyulko, O; Milecki, P; Nederman, T; Ng, S; Pili, R; Pouget, JC; Schwartsmann, G; Sternberg, C; Thanos, A; Tuvesson, H; Vogelzang, N; Werbrouck, P | 1 |
| Armstrong, AJ; George, D; Halabi, S; Harrison, MR; Healy, P; Humeniuk, MS; Kephart, J; Martinez, E; Mundy, K; Szmulewitz, R; Winters, C | 1 |
3 review(s) available for carbostyril and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
Topics: Androstenes; Antineoplastic Agents; Disease-Free Survival; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms, Castration-Resistant; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer: A meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quinolones; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2018 |
[Tasquinimod: How to act on microenvironment in metastatic prostate cancer].
Topics: Humans; Male; Prostatic Neoplasms, Castration-Resistant; Quinolines; Quinolones; Tumor Microenvironment | 2015 |
8 trial(s) available for carbostyril and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.
Topics: Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Pyridines; Quinolones; Receptors, Androgen; Treatment Outcome | 2022 |
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; International Agencies; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Quinolones; Survival Rate; Taxoids; Treatment Outcome | 2017 |
Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05).
Topics: Aged; Aged, 80 and over; Benzimidazoles; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Tasquinimod: a novel drug in advanced prostate cancer.
Topics: Angiogenesis Inhibitors; Double-Blind Method; Drug Evaluation; Humans; Male; Maximum Tolerated Dose; Prostatic Neoplasms, Castration-Resistant; Quinolines; Quinolones | 2013 |
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer.
Topics: Biomarkers, Tumor; Bone Neoplasms; C-Reactive Protein; Disease-Free Survival; Humans; L-Lactate Dehydrogenase; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quinolines; Quinolones; Survival Analysis; Vascular Endothelial Growth Factor A | 2013 |
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Topics: Bone and Bones; Bone Neoplasms; Diagnostic Imaging; Disease Progression; Disease-Free Survival; Double-Blind Method; Humans; Male; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quinolines; Quinolones; Radiography; Retrospective Studies | 2014 |
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quinolones | 2016 |
Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Quinolones; Survival Rate; Taxoids; Treatment Outcome | 2017 |
7 other study(ies) available for carbostyril and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
Topics: Alternative Splicing; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Male; Mitogen-Activated Protein Kinase Kinases; Neoplasm Recurrence, Local; Prognosis; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinolones; Receptors, Androgen; Signal Transduction; Thiophenes; Transcriptional Activation | 2021 |
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.
Topics: Androstenes; Androstenols; Anilides; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Humans; Imidazoles; Ipilimumab; Male; Naphthalenes; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Quinolines; Quinolones; Radioisotopes; Radium; Taxoids; Thionucleotides; Tissue Extracts | 2013 |
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzimidazoles; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neovascularization, Pathologic; Osteoblasts; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Stromal Cells; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Biological Availability; Biotransformation; Capillary Permeability; Cell Line, Tumor; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Inbred C57BL; Mice, Nude; Neovascularization, Physiologic; Orchiectomy; Prostatic Neoplasms, Castration-Resistant; Protein Binding; Quinolines; Quinolones; Serum Albumin; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Dovitinib reduces prostate cancer bone metastases.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Bone Neoplasms; Humans; Male; Mice; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Quinolones; Receptors, Fibroblast Growth Factor | 2014 |
Mitotic arrest induced in human DU145 prostate cancer cells in response to KHC-4 treatment.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; G2 Phase Cell Cycle Checkpoints; Humans; Male; Mitosis; Morpholines; Prostatic Neoplasms, Castration-Resistant; Quinolones; Up-Regulation | 2016 |
Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cytokines; Heterografts; Humans; Immune Tolerance; Inflammation; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Osteoblasts; Osteogenesis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quinolines; Quinolones; Tibia; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |